A prospective observational study of pancreatic cancer risk in men and women with pathogenic variants in BRCA1 or BRCA2 Authors: Eli Marie Grindedal, Manuela Zucknick, Sigrid Tronsli Hovland, Tom K Grimsrud, Lovise Mæhle Published: 2025 ABSTRACT AbstractBackgroundBRCA1 and BRCA2 carriers have increased risk of pancreatic cancer (PC). We have studied prospective incidence rate and cumulative risk of PC in a large cohort of confirmed carriers.MethodsBRCA1/2 carriers without PC prior to genetic testing were identified from the clinical registry at Section for Hereditary Cancer, Oslo University Hospital. Cancer diagnoses were collected from Cancer Registry of Norway (CRN). Standardized incidence ratios (SIRs) were derived from national reference rates. The Kaplan-Meier method was used to calculate cumulative risk.ResultsAmong 2681 BRCA1 carriers, we observed 13 cases versus 4.73 expected (SIR 2.75, 95% CI 1.46–4,70). In 1476 BRCA2 carriers, we observed 9 cases versus 1.89 expected (SIR 4.76, 95% CI 2.18–9.04). Suggestively, there were higher risks among female BRCA2 carriers (SIR 6.52, 95% CI 2.82–12.85, 8 cases) and male BRCA1 carriers (SIR 5.51, 95% CI 2.52–10.47, 9 cases), who had cumulative risks at 70 years of 1.2% and 2.5% respectively.ConclusionsBRCA1/2 carriers had three times more cases of PC than expected, suggestively higher among female BRCA2 and male BRCA1 carriers. Cumulative risk of PC at 70 years in the latter two groups was less than 3% (0.5% and 0.7% in all Norwegian males and females observed until age 70 based on population data). Background The tumor suppressor genes BRCA1 and BRCA2 were identified in the mid-1990s. Since then, numerous studies have confirmed that women with pathogenic variants in these genes (BRCA1/2 carriers) have a high lifetime risk of developing breast and ovarian cancer [1, 2]. Somewhat later research showed that male BRCA2 carriers have an elevated risk of prostate cancer [3]. Clinical guidelines have been established for early detection and/or prevention of breast, ovarian and prostate cancer in BRCA1/2 carriers. To provide carriers with evidence-based advice regarding follow-up, it is important to know whether pathogenic variants in BRCA1/2 are associated with increased risk of other common or severe cancers, such as pancreatic cancer (PC) known to have a high lethality. In retrospective studies, estimates of the relative risk (RR) of PC have been reported between 2.2 and 3.2 for BRCA1 carriers, and between 3.5 and 6.6 for BRCA2 carriers [4–7]. Retrospective studies are based on historical data on cancer reported in families before genetic testing was done. The estimates may therefore be affected by selection bias, as the families with the strongest family histories of cancer are more inclined to be referred for genetic testing than those with fewer individuals with cancer. In addition, the study cohorts often include both carriers and individuals who have not been tested, and the estimates thereby become more uncertain. In a recent large, international retrospective study it was also noted that the data on family history of cancer was self-reported, and that 7–40% of the diagnoses lacked information on age [7]. To our knowledge, only one prospective study has investigated risk of PC in female BRCA1/2 carriers [8], reporting similar but imprecise risk estimates for the two genes, with standardized incidence ratios (SIR) of 2.6 (95% confidence interval (CI) 0.95–5.67, six cases) for BRCA1 and 2.1 (95% CI 0.25–7.58, two cases) for BRCA2 (CIs derived by the authors of the present article). The low statistical strength allowed no firm conclusion for BRCA2 (p = 0.3). More than 80% of PC patients are diagnosed with advanced stage disease, when surgery is no longer possible [9]. Still, the overall 5-year relative survival has improved over the last 20 years from around 3% to 15% for pancreatic cancer, all histological subtypes taken together [10]. Some studies have indicated that annual surveillance with magnetic resonance imaging (MRI) and/or endoscopic ultrasound (EUS) may lead to a higher number of resectable cancers and an improved short time survival [11–16]. It has been argued that surveillance should be done in an academic setting to select the high-risk individuals most likely to benefit from it [17]. Thus, it is important to obtain precise risk estimates in prospective studies of large cohorts of confirmed carriers. The information is also important for the carriers themselves and their families. Section for Hereditary Cancer (SHC) at Oslo University Hospital (OUH), has offered genetic testing of BRCA1/2 since 1994. In August 2020, our clinical registry included 4453 confirmed carriers of pathogenic or likely pathogenic BRCA1/2 variants. The Cancer Registry of Norway (CRN) continuously records individual data on new cancers diagnosed nationally. Linkage to these data is facilitated by unique personal identity numbers, providing reliable data on all PC diagnoses among BRCA1/2 carriers in our cohort since 1960, as well as equally reliable comparison data on incidence from the general Norwegian population. The aim of this study was to obtain prospective estimates of PC incidence in confirmed male and female BRCA1/2 carriers compared with the general population, and to investigate their cumulative risk of PC. A secondary aim was to investigate PC incidence in carriers with and without a recorded family history of the disease. Methods Clinical registry for hereditary cancer at Section of Hereditary Cancer (SHC), Oslo University Hospital SHC has offered genetic counseling and testing for familial cancer and hereditary syndromes since the early 1990s. When an individual is referred to the section, a record is created in the section’s clinical registry for hereditary cancer for him or her. For each individual, information is registered on date of birth, personal cancer history, and results of performed genetic analyses. During counseling, information is collected regarding family history of cancer. When the diagnosis is uncertain, detailed information is collected from CRN or medical files. Some family histories of cancer therefore are self-reported, and some are confirmed. The purpose is to create a family tree for a visual image of how individuals in a family are related, what types of cancer have been diagnosed, whether and when they have been genetically tested, and test results. Some families in the registry span 5–6 generations. Genetic testing of BRCA1 and BRCA2 at SHC BRCA1 and BRCA2 were identified in 1994 and 1995. Until around 2010, the availability of genetic testing for these genes was limited. Genetic analyses could only be done in families with a strong family history of breast and/or ovarian cancer, when it was possible to get a blood sample from family members diagnosed with such cancer. Most families were only tested for 6–10 known Norwegian BRCA1/2 founder mutations. For many families, blood samples were stored for years before they could be analyzed, or sequenced, and some patients had passed away before the variant was identified. From 2010, all individuals who fulfilled criteria for genetic testing were offered sequencing and Multi Ligation Probe Amplification (MLPA) of both genes. As genetic testing has become more available, the criteria for testing have become more liberal. Today, an individual with one first-degree relative who has breast, prostate or colorectal cancer ≤ 60 years, or one first-degree relative who has ovarian cancer or pancreatic cancer regardless of age, will be offered testing with a panel of 30 genes, including BRCA1/2. Genetic testing is also offered outside of these criteria based on an overall assessment of the family history of cancer. In Norway, genetic testing is largely covered by the Norwegian Health Economics Administration (HELFO), and the patient only pays a small deductible. Genetic services are therefore in principle available to the whole population regardless of income or employment status. Knowledge about hereditary breast and ovarian cancer has increased in the general population during the last 10 years, and even in Norway, we saw a 50% increase in the number of referred patients after Angelina Jolie shared her story about being a BRCA1 carrier and undergoing prophylactic surgery, referred to as the “Angelina effect” [18]. Methods All women and men who had tested positive for a pathogenic or likely pathogenic variant in BRCA1/2 were identified in the clinical registry at SHC by August 2020. Information on all diagnosed cancers in these individuals was collected from CRN, using the unique personal identification numbers covering all Norwegian citizens alive in or born after 1960. The CRN is close-to-complete [19] and has registered cancer diagnoses in Norway since 1953. At the time of data collection, CRN had completed its registration for 2019. Last date of observation for the study was therefore set to 31st of December 2019, and the participants were followed until the diagnosis of PC, death/emigration or end of follow up, whichever came first. We collected information on all cancer diagnoses (ICD10 codes and date of diagnosis), and for PC, classification of histology was provided. From the clinical registry at SHC, we collected information on date of birth, gender, affected gene and variant. We manually extracted data on any recorded first degree/second degree/any relative diagnosed with PC. Some of these diagnoses were confirmed from CRN or hospital records. We also registered whether these relatives were carriers or whether they had unknown carrier status. For individuals who had been diagnosed with PC we registered whether they had relatives with PC prior to their own diagnosis. To reduce the likelihood of selection bias, we identified a sub-cohort within the total cohort of carriers, including only those who had tested positive for a BRCA1/2 variant while they were alive (“at risk” of PC), not diagnosed with PC before they were genetically tested, and tested before 31st of December 2019. Only PCs diagnosed in this sub-cohort after they had been found to be a BRCA1/2-carriers were considered prospective and the analyses of SIR and cumulative risk were only performed within this sub-cohort, referred to as the prospective cohort in the following. Statistics Only pancreatic adenocarcinomas were included in the descriptive analyses, the logistic regression and the analysis of cumulative risk. Because population data on frequencies of PC from the CRN includes all histologies, we included all histological types of prospective cases for the SIR analysis. SIR was calculated for comparing incidence of PC in this cohort with the incidence in comparable age, gender and observation period distributions (data obtained from CRN). 95% confidence intervals for SIR were derived assuming a Poisson distribution of the observed cases. Statistical tests were performed as two-sided tests at the 0.05 significance level. A Cox proportional hazards model was fitted to analyze associations between cumulative risk of PC and covariates gender and gene status (BRCA1/2 variant status) and to calculate hazard ratios for these factors. Additional models included the interaction effect between gender and gene, and family history. Stata/SE Version 16.1 was used for SIR and cumulative risk analyses. Results The total cohort included 4453 BRCA1/2 carriers, 2851 (64.0%) BRCA1 carriers, 1597 (35.9%) BRCA2 carriers, and 5 carriers with a pathogenic variant in both BRCA1 and BRCA2. The carriers belonged to 1319 registered families in the clinical registry. The prospective cohort included slightly fewer individuals, 4162 carriers, 2681 (64.4%) BRCA1 carriers, 1476 (35.5%) BRCA2 carriers, and 5 carriers of both a BRCA1 and a BRCA2 variant. Median age at genetic testing for the prospective cohort was 44 years (Table 1). Sixty three percent (2628/4162) were tested before 50 years and 81% (3361/4162) were tested before 60 years. Age distributions for age at genetic testing and by end of follow up are shown in Figs. 1 and 2. Table 1Description of study cohort.Total cohortAllBRCA1BRCA2BRCA1 and BRCA2Number of carriers4453285115975Female3204 (72%)2072 (73%)1127 (71%)5Male1249 (28%)779 (2 7%)470 (29%)–Age (median) at positive test result44434639Tested after death172 (4%)116 (4%)56 (4%)–Tested while alive4281 (96%)2735 (96%)1541 (96%)5Total number of families13198234933Number of families with more than one member registered1091 (83%)689 (84%)399 (81%)3*Average number of carriers per family with more than one individual registered555Prospective cohortNumber of carriers4162268114765Female2969 (71%)1928 (72%)1036 (70%)5Male1193 (29%)753 (28%)440 (30%)Age (median) at positive test result44434639Follow up years counted from birth221036.7143241.377582.1213.3Mean follow up years counted from birth53.153.452.642.7Follow up years counted from genetic testing33650.224501.49128.720.1Mean follow up years counted from genetic testing8.19.16.24.0Total number of families12407814563Number of families with more than one member registered1041 (84%)663 (85%)375 (82%)3*Average number of carriers per family with more than one member registered555– Description of study cohort. Age distribution of BRCA1/2 carriers at genetic testing. Age distribution of BRCA1/2 carriers at date of last follow up/date of death/date of pancreatic cancer diagnosis. Pancreatic cancer in the total cohort In the total cohort, 33 (33/4453 = 0.7%) BRCA1/2 carriers had been diagnosed with PC, one of them a sarcoma located in the pancreas diagnosed in a female BRCA1 carrier. The rest were adenocarcinomas. Excluding the sarcoma, the 32 PCs (32/4453 = 0.7% of all carriers) were distributed with 16 (16/2851 = 0.6%) in BRCA1 carriers and 16 (16/1597 = 1%) in BRCA2 carriers. None of the 5 combined BRCA1 and a BRCA2 carriers had been diagnosed with PC. Mean age at diagnosis was 67 years (range 37–87) for all. The gender distribution showed the highest proportion of PC among male BRCA1 carriers and female BRCA2 carriers, respectively (Table 2). Table 2Pancreatic cancer in the study cohort.Total cohort of carriersCategory of carriersAll carriers* (n = 4453)BRCA1 (n = 2851)BRCA2 (n = 1597)No. of pancreatic cancers (percent of category)32 (0.7%)16 (0.6%)16 (1%)F (n = 3204)19 (0.6%)M (n = 1249)13 (1.0%)F (n = 2072)5 (0.2%)M (n = 779)11 (1.4%)F (n = 1127)14 (1.2%)M (n = 470)2 (0.4%)Mean age at diagnosis (range)66.9 (37.1–87.2)67.2 (47.7–87.2)64.5 (37.1–87.0)F67.8 (37.1–87.2)M63.0 (44.6–82.5)F72.1 (56.0–87.2)M66.7 (47.7–82.5)F66.2 (37.1–87.0)M52.2 (44.6–59.8)No. of cases with first-degree relatives with variant and PC (percent of all PCs in category)5 (15.6%)2 (12.5%)3 (18.8%)No. of cases with second degree relatives with variant and PC (percent of all PCs in category)1 (3.1%)-1 (6.3%)No. of cases with any relative with variant and PC (percent of all PCs in category)7 (21.9%)3 (18.8%)4 (25.0%)No. of cases with first-degree relatives with PC (percent of all PCs in category)7 (21.9%)3 (18.8%)4 (25.0%)No. of cases with second degree relatives with PC (percent of all PCs in category)4 (12.5%)2 (12.5%)2 (12.5%)No. of cases with any relative with PC (percent of all PCs in category)12 (37.5%)6 (37.5%)6 (37.5%)Prospective cohortCategory of carriersAll carriers* (n = 4162)BRCA1 (n = 2681)BRCA2 (n = 1476)Pancreatic cancer (percent of category)21 (0.5%)12 (0.4%)9 (0.6%)F (n = 2969)11 (0.4%)M (n = 1193)10 (0.8%)F (n = 1928)3 (0.2%)M (n = 753)9 (1.2%)F (n = 1036)8 (0.8%)M (n = 440)1 (0.2%)Mean age at diagnosis (range)67.0 (37.1-87.2)70.1 (47.7-87.2)62.8 (37.1-87.0)F67.3 (37.1-87.2)M66.5 (47.7-82.5)F78.4 (66.2-87.2)M67.3 (47.7-82.5)F63.2 (37.1-87.0)M59.8No. of cases with first-degree relatives with variant and PC (percent of all PCs in category)2 (9.5%)1 (8.3%)1 (11.1%)No. of cases with any relative with variant and PC (percent of all PCs in category)4 (19%)2 (16.7%)2 (22.2%)No. of cases with first-degree relatives with PC (percent of all PCs in category)3 (14.3%)1 (8.3%)2 (22.2%)No. of cases with any relative with PC (percent of all PCs in category)7 (33.3%)4 (33.3%)3 (33.3%) Pancreatic cancer in the study cohort. F (n = 3204) 19 (0.6%) M (n = 1249) 13 (1.0%) F (n = 2072) 5 (0.2%) M (n = 779) 11 (1.4%) F (n = 1127) 14 (1.2%) M (n = 470) 2 (0.4%) F 67.8 (37.1–87.2) M 63.0 (44.6–82.5) F 72.1 (56.0–87.2) M 66.7 (47.7–82.5) F 66.2 (37.1–87.0) M 52.2 (44.6–59.8) F (n = 2969) 11 (0.4%) M (n = 1193) 10 (0.8%) F (n = 1928) 3 (0.2%) M (n = 753) 9 (1.2%) F (n = 1036) 8 (0.8%) M (n = 440) 1 (0.2%) F 67.3 (37.1-87.2) M 66.5 (47.7-82.5) F 78.4 (66.2-87.2) M 67.3 (47.7-82.5) F 63.2 (37.1-87.0) M 59.8 The 32 patients with PC belonged to 29 different families. Five of them (5/32 = 15.6%) had a first-degree relative, and 7 (7/32 = 21.9%) any relative (carrier or obligate carrier of the same pathogenic variant) reported with PC before their own PC diagnosis (Table 2). The 32 PC cases occurred in carriers of altogether 21 different pathogenic or likely pathogenic variants. The most common variants in the PC cases were BRCA1 c.1016dup (4 cases) and BRCA2 c.5217_5223del (4 cases). These two variants represent the most common BRCA1 and BRCA2 variants in the Norwegian population. Three other BRCA1 variants (c.2351_2357del, c.1556del and c.3331_3334del) and two BRCA2 variants (c.2808_2811del and dup exon 20) were all observed in two PC cases each. Fourteen variants were only observed once among the PC cases (Supplementary table 2). Pancreatic cancer in the prospective cohort In the prospective cohort there were 21 (21/4162 = 0.5%) cases of PC (adenocarcinomas), 12 among BRCA1 carriers (12/2681 = 0.4%) and 9 among BRCA2 carriers (9/1476 = 0.6%). In addition to the 21 adenocarcinomas, the sarcoma of the pancreas was found prospectively in a female BRCA1 carrier. The proportion among BRCA1 carriers was 3/1928 = 0.2% for female and 9/753 = 1.2% for male carriers. Among BRCA2 carriers, 8/1036 = 0.8% women and 1/440 = 0.2% men were diagnosed with PC. Seventeen out of 21 (81%) of all PCs were diagnosed in male BRCA1 carriers or female BRCA2 carriers. Mean age at onset was 67 years (range 37–87). Two out of the 21 (9.5%) had a first-degree relative carrying the same variant and diagnosed with PC prior to their own diagnosis, and 4/21 (19%) had any relative (including the first degree relative) with the same variant and PC (Table 2). Characterization of families with cases of pancreatic cancer In addition to the 33 diagnoses (32 adenocarcinomas and one sarcoma) collected from CRN for this study, there were 136 individuals recorded with a confirmed or unconfirmed diagnosis of PC in the 1319 families with a pathogenic variant in BRCA1/2. These 136 PC patients were either obligate carriers or had unknown carrier status (one of the obligate carriers had both a BRCA1 and a BRCA2 variant). The total of 169 individuals with PC belonged to 139 (10.5%) out of all 1319 families. In 115 (83%) out of the 139 families, only a single PC case was recorded. Eighteen families (18/139 = 12.9%) had two PC cases, and five families (5/139 = 3.6%) had three or four PC cases, three families with BRCA2 variants and two families with BRCA1 variants. Standardized incidence ratios of pancreatic cancer in prospective cohort For the calculations of SIR, we included the sarcoma diagnosed prospectively in a female BRCA1 carrier, giving a total of 22 prospective PC cases. In all carrier sub-groups by gender and gene, there were more cases of PC observed than expected from the background rates, although it was a statistically significant excess only for the sub-groups of male BRCA1 carriers and female BRCA2 carriers, as indicated by the 95% CI not including 1 for these subgroups (Table 3). Among the 2681 BRCA1 carriers of both genders, the SIR was 2.75 (95% CI 1.46–4.70, 13 cases), and among the 1476 BRCA2 carriers, the SIR was 4.46 (95% CI 2.18–9.04, 9 cases). Elevated risks were most clearly seen in female BRCA2 carriers with an SIR of 6.52 (95% CI 2.82–12.85, 8 cases), and in male BRCA1 carriers with SIR = 5.51 (95% CI 2.52–10.47, 9 cases). The number of cases in the remaining gender-specific groups was low, with corresponding imprecise SIRs: female BRCA1 carriers with an SIR of 1.54 (95% CI 0.42–3.94, 4 cases) and male BRCA2 carriers with an SIR of 2.2 (95% CI 0.0.6–12.27, 1 case) (Table 3). Table 3Standardized incidence ratios in the prospective cohort.ExpectedObservedSIR (95% confidence interval)All carriers6.62223.32 (2.08–5.03)All women3.83123.13 (1.62–5.47)All men2.09104.79 (2.3–8.82)BRCA1 men and women4.73132.75 (1.46–4.70)BRCA1 women2.641.54 (0.42–3.94)BRCA1 men1.6395.51 (2.52–10.47)BRCA2 men and women1.8994.76 (2.18–9.04)BRCA2 women1.2386.52 (2.82–12.85)BRCA2 men0.4512.2 (0.06–12.27) Standardized incidence ratios in the prospective cohort. For the sub-groups with the largest numbers of cases, i.e., female BRCA2 carriers and male BRCA1 carriers, we looked at risks according to family history of PC. There was a higher number of observed vs expected number of cases both among those who had a family history of PC and among those with no such history (Supplementary table 1). Cumulative risk of pancreatic cancer in prospective cohort Cumulative risk of developing PC by 70 years was 0.3% for female BRCA1 carriers and 2.5% for male carriers. For BRCA2 carriers it was 1.2% for females and 0.7% for males (Table 4). Based on the observed SIRs and estimates for cumulative risk for the different groups, we hypothesized that male BRCA1 carriers had a higher risk than female BRCA1 carriers, and that female BRCA2 carriers had a higher risk than male BRCA2 carriers. We tested this by using a Cox proportional hazard regression model including gender and gene as covariates. We found that there was a statistically significant interaction effect between gender and BRCA1/BRCA2 (p = 0.043). When we added family history of PC to the model, gender and gene and its interaction remained statistically significant. A family history of one or more relatives with PC resulted in an increase in the hazard for being diagnosed with PC in this model, for both genes, but the hazard ratio was not statistically significant (HR 2.33, p = 0.07, 95% CI 0.93-5.81). Table 4Cumulative risk of pancreatic adenocarcinoma among BRCA1/2 mutation carriers in the prospective cohort.50 years60 years70 years80 yearsAll carriers0.1% (SE 0.000)[0.000, 0.002]*0.2% (SE 0.001)[0.001, 0.006]1.1% (SE 0.003)[0.006, 0.019]1.6% (SE 0.005)[0.008, 0.027]BRCA1All0.1% (SE 0.001)[0.000, 0.003]0.1% (SE 0.001)[0.000, 0.003]1.2% (SE 0.004)[0.005, 0.022]1.2% (SE 0.004)[0.005, 0.022]Female carriers0.3% (SE 0.003)[0.000, 0.014]0.3% (SE 0.003)[0.000, 0.014]Male carriers0.2% (SE 0.002)[0.000, 0.010]0.2% (SE 0.002)[0.000, 0.010]2.5% (SE 0.01)[0.011, 0.049]2.5% (SE 0.01)[0.011, 0.049]BRCA2All0.1% (SE 0.001)[0.000, 0.005]0.6% (SE 0.003)[0.002, 0.014]1% (SE 0.004)[0.004, 0.022]2.5% (SE 0.012)[0.009, 0.057]Female carriers0.1% (SE 0.001)[0.000, 0.007]0.5% (SE 0.003)[0.001, 0.015]1.2% (SE 0.005)[0.004, 0.027]3.2% (SE 0.016)[0.010, 0.075]Male carriers0.7% (SE 0.007)[0.001, 0.034]0.7% (SE 0.007)[0.001, 0.034]0.7% (SE 0.007)[0.001, 0.034]Norwegian women**0.04%0.2%0.5%1.2%Norwegian men**0.04%0.2%0.7%1.5%*95% confidence intervals.**Derived from summing one-year age-specific rates of all histological types of PC [10]. Cumulative risk of pancreatic adenocarcinoma among BRCA1/2 mutation carriers in the prospective cohort. 0.1% (SE 0.000) [0.000, 0.002]* 0.2% (SE 0.001) [0.001, 0.006] 1.1% (SE 0.003) [0.006, 0.019] 1.6% (SE 0.005) [0.008, 0.027] 0.1% (SE 0.001) [0.000, 0.003] 0.1% (SE 0.001) [0.000, 0.003] 1.2% (SE 0.004) [0.005, 0.022] 1.2% (SE 0.004) [0.005, 0.022] 0.3% (SE 0.003) [0.000, 0.014] 0.3% (SE 0.003) [0.000, 0.014] 0.2% (SE 0.002) [0.000, 0.010] 0.2% (SE 0.002) [0.000, 0.010] 2.5% (SE 0.01) [0.011, 0.049] 2.5% (SE 0.01) [0.011, 0.049] 0.1% (SE 0.001) [0.000, 0.005] 0.6% (SE 0.003) [0.002, 0.014] 1% (SE 0.004) [0.004, 0.022] 2.5% (SE 0.012) [0.009, 0.057] 0.1% (SE 0.001) [0.000, 0.007] 0.5% (SE 0.003) [0.001, 0.015] 1.2% (SE 0.005) [0.004, 0.027] 3.2% (SE 0.016) [0.010, 0.075] 0.7% (SE 0.007) [0.001, 0.034] 0.7% (SE 0.007) [0.001, 0.034] 0.7% (SE 0.007) [0.001, 0.034] *95% confidence intervals. **Derived from summing one-year age-specific rates of all histological types of PC [10]. Discussion To our knowledge, this is the first prospective study of PC providing risk estimates for confirmed BRCA1/2 carriers. Overall, there were three times more cases of PC among known carriers than expected in a similar cohort with population risk. We found a statistically significant higher incidence of PC for both BRCA1 and BRCA2 carriers, with SIRs of 2.75 and 4.76, respectively. However, when SIR was calculated for men and women separately, statistically significant increased incidence was only evident in male BRCA1 carriers (SIR 5.51) and female BRCA2 carriers (SIR 6.52), although the numbers of observed cases were higher than expected also for the remaining groups. The calculated cumulative risks by age 70 were somewhat moderate with 2.5% (male BRCA1) and 1.2% (female BRCA2), i.e. around two to three times the cumulative risk in the reference population (0.7% and 0.5% in all Norwegian males and females observed until age 70, 2017–2021, CRN data). Our observations thus confirmed the association between pathogenic germline variants in BRCA1 and BRCA2 and PC risk. Retrospective studies have previously demonstrated a relative risk of PC between 2.2 and 3.2 for BRCA1 carriers, and between 3.5 and 6.6 for BRCA2 carriers [4–7]. Thus, our estimates lie largely within the ranges suggested in earlier retrospective studies. We found that increased incidence was especially pronounced in male BRCA1 carriers (SIR 5.51) and female BRCA2 carriers (SIR 6.52). Cox proportional hazard regression models confirmed that there was a statistically significant interaction effect between gender and gene, which indicated that the PC cumulative risk differs between male and female carriers. Still, there were small numbers in some groups and the results should be interpreted with caution. Only one previous study has calculated gender-specific risks in carriers of BRCA1/2 mutations [7]. It was a retrospective study, and the authors reported on data from 3184 BRCA1 and 2157 BRCA2 families, with individuals followed from birth until first primary cancer diagnosis. No statistically significant difference in relative risk between female and male BRCA1/2 carriers was found. In their study, female and male BRCA1 carriers had a relative risk of 4.27 (95% CI 2.01-9.05) and 1.92 (95% CI 1.12-3.28), and female and male BRCA2 carriers 4.34 (95% CI 2.19-8.62) and 2.96 (95% CI 1.78-4.94) [7]. Their study is different from our current study in several aspects: It is based on retrospective data, they only included the first cancer diagnosis and they included confirmed and assumed carriers, These differences hamper a direct comparison with our observations, and further prospective studies with large sample sizes are needed to confirm the possible gender difference in risk of PC among BRCA1 and BRCA2 carriers. Due to the limited knowledge on the long-term benefit of PC surveillance, the CAPS-consortium (International Cancer of the Pancreas Screening Consortium) recommends that screening is only offered to those at the highest risk and within an academic setting [17]. They have previously suggested that surveillance is offered to those with a lifetime risk of more than 5% or a fivefold increased relative risk [20]. The current NCCN (National Comprehensive Cancer Network) guidelines recommend that surveillance is considered in all BRCA2 carriers irrespective of family history of PC, and the guidelines issued by ASGE (American Society of Gastrointestinal Endoscopy) recommends surveillance for both BRCA1 and BRCA2 carriers [21, 22]. In our study, both male BRCA1 carriers and female BRCA2 carriers had a more than fivefold increase in PC incidence compared to the general population. However, none of the groups of carries had a cumulative risk of PC of 5% at the age of 80. For female BRCA2 carriers it was 1.2% at 70 years and 3.2% at 80 and for male BRCA1 carriers it was 2.5% at 70 and 80 years. For male BRCA2 and female BRCA1 carriers it was below 1% at 80 years. The Norwegian guidelines for diagnostics and treatment of PC recommend that surveillance is only done as part of research [23]. Based on this recommendation we have established the PREPAIRD-study (Personalized suReillance for Early detection and prevention of Pancreatic cAncer in hIgh Risk inDividuals), where individuals with hereditary or familial increased risk of PC are offered annual MRI and assessment of HbA1c, lipid status, new onset diabetes and unintentional weight loss. Inclusion is open for carriers of pathogenic variants in STK11, CDKN2A, TP53 and PRSS1 and individuals belonging to families without identified pathogenic variants where there have been three close relatives with PC or two close relatives with a mean age at diagnosis below 60 years (familial pancreatic cancer (FPC)). BRCA1/2 carriers are currently not included in the study unless they also fulfill the criteria set for those with FPC. Based on the results from the current study, we have not changed the inclusion criteria. This will be reconsidered if future prospective studies with larger cohorts, longer follow-up time and a higher number of PC cases show that all or sub-groups of BRCA1/2 carriers have a higher PC risk. Family history of PC is often included in guidelines for screening: The CAPS-consortium recommends that surveillance is offered to BRCA2 carries who have at least one affected first-degree relative with PC [17] and the NCCN guidelines recommend that it is considered in BRCA1 carriers with a family history of PC [21]. Two recent studies found no association between having a first-degree relative with PC and PC risk, but they included only 294 and 204 BRCA1/2 carriers respectively [24, 25]. A secondary aim of our study was to investigate the impact of family history on PC risk. We found that a family history of one or more relatives with PC gave a HR of 2.33 (p = 0.07, 95% CI = 0.93, 5.81, based on 21 cases of PC) for being diagnosed with PC for both genes, but the finding was not statistically significant. We also found a higher number of observed vs expected cases of PC in female BRCA2 carriers and male BRCA1 carriers both with and without a family history of PC. Our data also indicated that family history of PC had a limited predictive value. In the prospective cohort, only 25% of the BRCA1 and 33% of the BRCA2 carriers who had been diagnosed with PC had reported a first or a second degree relative with PC. In other words, 65–75% of those who were diagnosed with PC after they were found to carry a BRCA1/2 mutation did not have a family history of the disease. This is in line with earlier reports where only a minority of PC patients found to be BRCA1/2 carriers had a relative with the disease [26, 27]. In the present study, among 139 families with a known case of PC, 83% of the families only had a single case of PC. Our combined observations indicate both that if all BRCA1/2 carriers are offered surveillance, a large number has to be screened to detect one PC, and that if surveillance is offered only to those with a family history, the majority of those who develop PC are not under surveillance. Further studies are needed to investigate the impact of family history on PC risk and also whether there are other risk factors, early warning signs or biomarkers for PC that can contribute to early detection and intervention among BRCA1/2 carriers. If there is a genotype-phenotype correlation, and different BRCA1/2 variants give different PC risks, some of the variation in risk estimates between different studies may be due to the distribution of variants in different study cohorts. Norway has several founder variants in BRCA1/2, and in 2018 the four most common BRCA1 founder variants accounted for 52% of BRCA1 carriers identified at SHC [28]. In the current study we observed that 4 cases of PC were found in carriers of BRCA1 c.1016dup and 4 in carriers of BRCA2 c.5217_5223del, the most common BRCA1 and BRCA2 founder variants in Norway [28]. If there is a significant difference in PC risk between different BRCA1/2 variants, and the Norwegian founder variants give a lower PC risk than more rare variants, we cannot exclude that this have affected our estimates. This needs to be explored in a larger dataset with a higher number of PC cases. This is a prospective study of PC risk in a cohort including only confirmed BRCA1/2 carriers and all PC diagnoses have been confirmed from CRN. The design of the study limits the risks of ascertainment bias found in studies based on retrospective data. Even though the prospective cohort included as many as 4162 carriers, mean follow-up years after genetic testing was 8 years and only 21 cases of PC had been diagnosed after genetic testing. We cannot exclude that more cases of PC will occur as the individuals in this cohort grow older, and this may affect the risk estimates. Even though we have offered testing of BRCA1/2 based on a personal or family history of cancers other than breast or ovarian for several years, our patient cohort may be biased by previous selection criteria for testing. If family history of PC impacts risk, more follow-up years may be required for it to become visible. Smoking and diabetes are some of the known risk factors for PC. We have no data on these factors in our study cohort, and do not know to what extent they have impacted our findings. In this prospective study including confirmed BRCA1/2 carriers, we observed around three times more cases of PC than expected from the reference population, with a higher risk suggested in BRCA2 than in BRCA1 carriers. There were higher numbers of observed than expected cases across gene and gender, most clearly seen in male BRCA1 carriers (SIR 5.51) and female BRCA2 carriers (SIR 6.52). The cumulative risk of PC at age 70 in these two groups of carriers was higher than that of the general population, but less than 3%. Our findings of differences in risk according to gene and gender need to be confirmed in other studies. Further studies are also needed to clarify whether BRCA1/2 carriers as a group are at sufficiently high risk to be recommended screening, and to elucidate the effect of family history of PC on risk. Supplementary information Supplementary table 1 Supplementary table 2 Acknowledgements The data for this study has been made available by the Cancer Registry of Norway. Preliminary findings have been presented as a poster at the International Symposium on Hereditary Breast and Ovarian Cancer in Montreal on the third of May 2023. The title of the poster was: Prospective Pancreatic Cancer in a Large Norwegian Cohort of Confirmed BRCA1/BRCA2 Carriers. The abstract was not published to other than the participants attending the conference. Author contributions Study design: EMG, LOM, TKG, MZ. Data collection: EMG, TKG. Data analysis: EMG, LOM, TKG, STH, MZ. Manuscript preparation: EMG, LOM, TKG, STH, MZ. Review of final manuscript: EMG, LOM, TKG, STH, MZ. Funding This study was funded by the Norwegian Cancer Society, grant number 212734-2019 “The Norwegian Cancer Society’s National Group of Expertise on Pancreatic Cancer Research”. Data Availability The data included in the study are stored on the secure server of Oslo University Hospital. They are available upon reasonable request. Competing interests The authors declare no conflict of interest. Ethics approval and consent to participate The study was approved by the Regional Ethics Committee (Approval number 2019/308) and the Data Protection Officer at Oslo University Hospital (Approval number 19/09703). The approval from the ethics committee included an exemption from the requirement to obtain consent from the participants. The study was performed in accordance with the Declaration of Helsinki. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Supplementary information The online version contains supplementary material available at 10.1038/s44276-025-00199-2. References Associated Data Supplementary Materials Supplementary table 1 Supplementary table 2 Data Availability Statement The data included in the study are stored on the secure server of Oslo University Hospital. They are available upon reasonable request.